MYQORZO (Aficamten) Patent Expiration, LOE Window & CMS Spending

MYQORZO (Aficamten) by Cytokinetics: FDA Orange Book core substance LOE 2039-01-18 (last listed 2042-07-15), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $8,910 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCytokinetics
FDA Application & PathwayN219083 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-01-18
Last Listed Patent or Exclusivity Date2042-07-15
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($8,910 intro WAC)